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Historically, basal forebrain lesions
have been carried out using toxins that
destroyed noncholinergic neurons in ad-
dition to cholinergic neurons. These le-
sions resulted in a broad array of learning
and memory deficits, which for the most
part are not observed when lesions are
made using toxins targeting cholinergic
neurons and sparing noncholinergic neu-
rons (Everitt and Robbins, 1997). The
novel contribution from Lin and Nicolelis
(2008) reminds us that the often-ne-
glected noncholinergic neurons of the
basal forebrain may play a fundamental
role in signaling motivational salience,
which may be useful for directing top-
down attention. Their results open a new
avenue of research that promises to help
unravel the mechanisms that link the pro-
cessing of appetitive and aversive stimuli
to different forms of attention during
learning and action.
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In this month’s issue ofNature Medicine, Town et al. suggest that peripheral macrophages invading the brain
reduce cerebral amyloidosis and thus may play a key role in the pathogenesis of Alzheimer’s disease (AD).
This observation intensifies the longstanding controversy of whether mononuclear cells such as macro-
phages and/or microglial cells are beneficial or detrimental in AD.The current discussion is already some
twenty years old: It was Henryk Wisniew-
ski who argued that microglia in culture
but not in vivo can phagocytose b-amyloid
fibrils. His conviction was based on ultra-
structural observations in Alzheimer’s
disease (AD) brains revealing an intimate
relationship of b-amyloid plaques with mi-
croglia, which were, however, never found
to harbor b-amyloid fibrils within their
lysosomal compartments. In contrast,
Wisniewski and colleagues described
phagocytosed b-amyloid fibrils in macro-
phages of elderly patients suffering from
fatal stroke—a rare complication in AD,8 Neuron 59, July 10, 2008 ª2008 Elsevier Iwhich certainly does not represent the
usual course of disease (Wisniewski
et al., 1991; Frackowiak et al., 1992).
During development, myeloid cells in-
vade the brain and differentiate into micro-
glia. Resident microglia in the adult brain
are thought to monitor their local environ-
ment and—in contrast to their peripheral
counterparts, namely monocytes and
extraneural tissue macrophages, which
are rapidly and efficiently repopulated
(Kennedy and Abkowitz, 1998)—resident
microglia appear to have a rather slow
turnover (Asheuer et al., 2004; Priller et al.,
2001).nc.In the brains of AD patients as well as
the respective transgenic mouse models,
microglia become activated and increase
in number in response to cerebral b-amy-
loidosis. The extent to which peripheral
macrophages/monocytes contribute to
this amyloid-associated microgliosis and
its significance for AD remains unclear
(Wyss-Coray, 2006).
In the current issue of Nature Medicine,
Town and colleagues (2008) crossed
CD11c-DNR mice, in which TGF-b-
Smad2/3 signaling is blocked in CD11c+
cells, to two distinct and widely used amy-
loid precursor protein (APP) transgenic
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Contrary to the authors’ initial expecta-
tions, they observed a >50% reduction of
both soluble and insoluble amyloid-b
peptide (Ab). Equally surprisingly, an
increase in cells morphologically and phe-
notypically most closely resembling brain-
infiltrating macrophages in the absence of
detrimental inflammatory side effects was
detectable in the brains of aged double-
transgenic APP/CD11c-DNR mice over
single-transgenic APP littermates (1.7-
fold by morphometric and 7-fold by
FACS analyses). Such an increase was
found neither in the brains of single
transgenic CD11c-DNR mice nor in youn-
ger, though already amyloid-depositing
APP/CD11c-DNR mice. Town and col-
leagues went on to show that inhibition
of TGF-b signaling in primary peripheral
macrophages increased the uptake of pre-
aggregated synthetic Ab in vitro. These
and other observations led the authors to
conclude that blockade of TGF-b signaling
in peripheral macrophages promotes brain
infiltration of these cells with subsequent
phagocytosis and attenuation of cerebral
b-amyloidosis (Town et al., 2008).
These findings recall results of another
recent study: by ablating bone marrow-
derived mononuclear cells in an APP
transgenic mouse model, Simard and
colleagues (2006) concluded that bone
marrow-derived macrophages, but not
resident microglia, are critical for restrict-
ing b-amyloid plaque burden. However,
the specificity of targeting exclusively pe-
ripheral macrophages was not quantified.
Previous studies using bone marrow chi-
meric mice revealed that infiltrating periph-
eral macrophages/monocytes represent
only a tiny portion (1%) of total CD11b+/
Iba1+ cells in the brains of normal mice. In
response to cerebral amyloidosis, an in-
crease in this invading cell population has
been reported in APP transgenic mice.
Yet only a subpopulation (20%) of amy-
loid plaques are the target of such infiltrat-
ing macrophages, on average with less
than one invading macrophage per amy-
loid plaque (Stalder et al., 2005; Simard
et al., 2006). It is a surprising but equally
interesting suggestion that a presumably
small number of invading phagocytes are
accountable for a significant Ab plaque
catabolism, as suggested by Simard et al.
(2006) and Town et al. (2008). Alternatively,
thoroughassessment isneededofwhetherother mechanisms than phagocytosis of
invading macrophages may explain the
described changes in amyloid burden.
It is important to note that recent studies
challenge data on the role of CNS invasion
of peripheral monocyte/macrophages, at
least when generated in irradiated bone
marrow chimeric mice (Ajami et al., 2007;
Mildner et al., 2007). These studies sug-
gest that the increase in microglia in re-
sponse to a variety of CNS lesions is
more a result of local microglial prolifera-
tion than of invasion of peripheral mononu-
clear cells. In contrast, significant CNS
invasion of peripheral cells would require
a breach of the blood-brain barrier, which
in either case may be damaged in the
course of cerebral amyloidosis (Winkler
et al., 2001).
The potential benefit and clinical im-
plication of therapeutically targeting
mononuclear cells to fight AD is further
substantiated by an additional recent re-
port by El Khoury et al. (2007). In this study,
AD mice deficient in the CC-chemokine
receptor-2 (Ccr2) exhibit a significantly
reduced recruitment of both peripheral
monocytes/macrophages and resident
microglia toward b-amyloid plaques and
display accelerated amyloid deposition.
While this finding does not resolve the
issue of the specific mononuclear cell
subtype in charge, it clearly supports the
notion of the importance of the innate
immune system in the pathogenesis of AD.
To further pave the way toward target-
ing elements of the innate immune axis
such as mononuclear cells to fight AD, ob-
vious open questions must be addressed.
These include the urgent need to improve
our knowledge on the origin of mononu-
clear cells in the setting of AD, i.e.,
whether exclusively bone marrow-de-
rived mononuclear cells, resident micro-
glia, dendritic cells, or, finally, all of them
hold promise in the treatment of AD. Since
CD11c is known to drive protein expres-
sion in the majority of dendritic cells and
even in subtypes of microglia (Bulloch
et al., 2008), it will be interesting to
learn whether the increase in cells most
closely resembling brain-infiltrating mac-
rophages in the recent study of Town
et al. (2008) is also attributable to other
mononuclear or myeloid cell types.
Further, proof of b-amyloid phagocytic
activity of resident microglia or invading
macrophages, i.e., engulfment of amyloidNefibrils with the later appearance of fibrils
in the lysosomal-phagosomal compart-
ments, is still lacking for the in vivo setting
in the above-cited animal studies. Thus,
mechanistic insights into how peripheral
macrophages, resident microglia, or both,
clear Ab in vivo are required (is it Ab endo-
cytosis, pinocytosis, or indirect degrada-
tion?). This is also of particular interest
in the context of Ab-vaccination where
microglia in an ex vivo assay have been
described to phagocytose Ab-antibody
decorated amyloid plaques (Bard et al.,
2000). Since Ab-vaccination is a promising
anti-AD interventional regime, it will be
important to dissect the mechanisms
involved, including the contribution of
microglia.
Finally, there is the need to carefully as-
sess Ab biochemistry, amyloid deposition,
and its variability with aging in the various
mouse models of AD along with its func-
tional implications. Equally important are
comparisons among these mouse models.
It is important to keep in mind that there
may be differences in the efficacy of mac-
rophage/monocyte-recruitment at differ-
ent stages of AD and in individual disease
models. Such analyses may also help to
explain the nonlinear increase in plaque
formation by Simard and colleagues
(2006), which was the basis for assigning
an amyloid-reducing capacity to blood-
borne macrophages in the latter study.
Henryk Wisniewski, after following our
debate, would possibly smile. Despite
the modern tools of molecular and trans-
genic approaches, we are still left with
questions he already asked some twenty
years ago. However, he would most likely
agree with us that the recent data on the
role of mononuclear cells is highly encour-
aging and should promote more research
on the role of the innate immune system in
AD. Only a thorough elucidation of basic
mechanisms will lead to the successful
identification of novel therapeutic or
prophylactic options and eventual safe
implementation of anti-AD regimens that
target the immune axis.
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